[1]
|
Office for National Statistics, London, “Cancer Statistics Registrations England (Series MB1) No 42, 2011,” 2013.http://www.ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations--england--series-mb1-/index.html
|
[2]
|
Welsh Cancer Intelligence and Surveillance Unit Cardiff, “Cancer Incidence in Wales, 2007-2011,” 2013.
http://www.wales.nhs.uk/sites3/page.cfm?orgid=242&pid=66227
|
[3]
|
Office for National Statistics, “Breast Cancer: Incidence, Mortality and Survival, 2010. Female Breast Cancer in England: Incidence and Mortality,” 2012.
http://www.ons.gov.uk/ons/dcp 171780_280355.pdf
|
[4]
|
“Herceptin (Trastuzumab) Summary of Product Characteristics,” 2013.
http://www. ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500 074922.pdf
|
[5]
|
S. Vescial, A. K. Baumgartner, V. R. Jacobs, M. Kiechle-Bahat, A. Rody, S. Loibl and N. Harbeck, “Management of Venous Port Systems in Oncology: A Review of Current Evidence,” Annals of Oncology, Vol. 19, No. 1, 2008, pp. 9-15. http://dx.doi.org/10.1093/annonc/mdm272
|
[6]
|
S. Hamizi, G. Freyer, N. Bakrin, E. Henin, A. Mohtaram, O. Le Saux and C. Falandry, “Subcutaneous Trastuzumab: Development of a New Formulation for Treatment of HER2-Positive Early Breast Cancer,” OncoTargets and Therapy, Vol. 6, 2013, pp. 89-94.
|
[7]
|
Department of Health, “Improving Outcomes: A Strategy for Cancer,” 2011.
https://www.gov.uk/ government/uploads/system/uploads/attachment_data/file/135516/dh_123394.pdf.pdf
|
[8]
|
Personal Social Services Research Unit (PSSRU) Unit “Costs of Health & Social Care,” 2011.
http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf
|
[9]
|
Roche Products Ltd., “Herceptin (Trastuzumab) Algorithm, RXUKHERC00419,” Data on File, 2012.
|
[10]
|
Roche Products Ltd., “Herceptin Mean Number of Doses in 1L HER2+ mBC. RXUKDONF00248,” Data on File. 2012.
|